Report of Foreign Issuer (6-k)
June 19 2017 - 4:34PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
6-K
REPORT OF
FOREIGN PRIVATE ISSUER
Pursuant to Rule
13a-16
or
15d-16
of the Securities Exchange Act of 1934
For the month of June 2017
Commission File Number:
001-36581
Vascular Biogenics Ltd.
(Translation of registrants name into English)
6 Jonathan
Netanyahu St.
Or Yehuda
Israel 6037604
(Address
of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form
20-F
or Form
40-F.
Form
20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(7): ☐
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule
12g3-2(b)
under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule
12g3-2(b):
82-
EXPLANATORY NOTE
Attached hereto and incorporated by reference herein is the registrants press release issued on June 19, 2017, entitled VBL Therapeutics
Provides Update on Long Term Survival in Phase 2 Trials of Patients with Multiple Tumor Types. This Report of Foreign Private Issuer on Form
6-K
shall be incorporated by reference into the Companys
registration statement on Form
F-3
(File
No. 333-207250),
filed with the Securities and Exchange Commission (the SEC) on October 2, 2015, to the
extent not superseded by information subsequently filed or furnished (to the extent the Company expressly states that it incorporates such furnished information by reference) by the Company under the Securities Act of 1933, as amended, or the
Securities Exchange Act of 1934, as amended.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
VASCULAR BIOGENICS LTD.
|
|
|
|
|
Date: June 19, 2017
|
|
|
|
By:
|
|
/s/ Dror Harats
|
|
|
|
|
Name:
|
|
Dror Harats
|
|
|
|
|
Title:
|
|
Chief Executive Officer
|
3
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Sep 2023 to Sep 2024